Patents by Inventor Arthur Glenn Romero

Arthur Glenn Romero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230104647
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive amination of cyclopropylamines.
    Type: Application
    Filed: June 15, 2022
    Publication date: April 6, 2023
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • Patent number: 11390590
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 19, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, Jian-Xie Chen, Xuemei Chen, He Zhao, Betina Biolatto, Elisabeth C. A. Brot, Zhihua Li, Xiaoming Liao
  • Publication number: 20220025424
    Abstract: The present disclosure relates to compositions and methods for producing stereoisomerically pure aminocyclopropanes.
    Type: Application
    Filed: August 16, 2017
    Publication date: January 27, 2022
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, He ZHAO, Betina BIOLATTO, Jian-Xie CHEN, Elisabeth C.A. BROT, Peter C. MICHELS, Venkat K. CHARI, Ian C. COTTERILL
  • Publication number: 20210179625
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 17, 2021
    Inventors: Arthur Glenn ROMERO, Kevin A. GONCALVES
  • Publication number: 20210139437
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Application
    Filed: August 16, 2017
    Publication date: May 13, 2021
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • Patent number: 10919900
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Magenta Therapeutics Inc.
    Inventor: Arthur Glenn Romero
  • Publication number: 20200123161
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Application
    Filed: September 13, 2019
    Publication date: April 23, 2020
    Inventors: Arthur Glenn ROMERO, Kevin A. GONCALVES
  • Patent number: 10457683
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: October 29, 2019
    Assignee: Magenta Therapeutics Inc.
    Inventor: Arthur Glenn Romero
  • Patent number: 10351572
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 16, 2019
    Assignee: Magenta Therapeutics Inc.
    Inventor: Arthur Glenn Romero
  • Publication number: 20190177330
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 13, 2019
    Inventor: Arthur Glenn Romero
  • Publication number: 20180298013
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Application
    Filed: April 12, 2018
    Publication date: October 18, 2018
    Inventors: Arthur Glenn ROMERO, Kevin A. GONCALVES
  • Publication number: 20180000846
    Abstract: The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).
    Type: Application
    Filed: June 13, 2017
    Publication date: January 4, 2018
    Inventors: Shaharyar Khan, Arthur Glenn Romero, Mikael C. Herlevsen
  • Patent number: 9707244
    Abstract: The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Gencia Corporation
    Inventors: Shaharyar Khan, Arthur Glenn Romero, Mikael C. Herlevsen
  • Patent number: 9434753
    Abstract: The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: September 6, 2016
    Assignee: Gencia Corporation
    Inventors: Shaharyar M. Khan, Robert Gadwood, Arthur Glenn Romero
  • Publication number: 20160022709
    Abstract: The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Shaharyar Khan, Arthur Glenn Romero, Mikael C. Herlevsen
  • Publication number: 20150005258
    Abstract: The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.
    Type: Application
    Filed: September 18, 2012
    Publication date: January 1, 2015
    Applicant: Genci Corporation
    Inventors: Shaharyar M. Khan, Robert Gadwood, Arthur Glenn Romero
  • Publication number: 20140088094
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Application
    Filed: November 8, 2011
    Publication date: March 27, 2014
    Applicants: Merck Sharp & Dohme Corp., Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur Glenn Romero, Chad A. Van Huis, Thomas Daniel Aicher, Carl Kaub, Matthew N. Mattson, William David Thomas, Karin Ann Sttein, Erik Krogh-Jespersen, Zhan Wang
  • Patent number: 8420646
    Abstract: The present invention is directed to tricyclic tetrahydroquinoline compounds of formula I, and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, R20 and X are as described herein and to pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: April 16, 2013
    Assignee: PAH P&U LLC
    Inventors: Michael Robert Barbachyn, Paul Joseph Dobrowolski, Alexander Ross Hurd, Dennis Joseph McNamara, John Raymond Palmer, Arthur Glenn Romero, J. Craig Ruble, Debra Ann Sherry, Lisa Marie Thomasco, Peter Laurence Toogood
  • Publication number: 20110092494
    Abstract: The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.
    Type: Application
    Filed: December 20, 2010
    Publication date: April 21, 2011
    Inventors: Michael Robert Barbachyn, J. Craig Ruble, Arthur Glenn Romero, Lisa Marie Thomasco, Alexander Ross Hurd, John Raymond Palmer, Peter Laurence Toogood, Dennis Joseph McNamara, Debra Ann Sherry, Paul Joseph Dobrowolski
  • Publication number: 20100022524
    Abstract: The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.
    Type: Application
    Filed: August 28, 2009
    Publication date: January 28, 2010
    Inventors: Michael Robert Barbachyn, J. Craig Ruble, Arthur Glenn Romero, Lisa Marie Thomasco, Alexander Ross Hurd, John Raymond Palmer, Peter Laurence Toogood, Dennis Joseph McNamara, Debra Ann Sherry, Paul Joseph Dobrowolski